ADVERTISEMENT
Trastuzumab, Pertuzumab, and Docetaxel Remains Standard of Care for Older Patients With HER2-Positive Metastatic Breast Cancer
Akihiko Shimomura, MD, PhD, National Center for Global Health and Medicine, Tokyo, Japan, discussed results from a phase 3 study which compared trastuzumab emtansine against standard-of-care trastuzumab, pertuzumab, and docetaxel to determine optimal treatment for older patients with HER2-positive metastatic breast cancer.
These results were first presented at the 2023 San Antonio Breast Cancer Symposium.
Source:
Shimomura A, Tamura K, Sasaki K, et al. A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in older patients with metastatic HER2-positive breast cancer. (JCOG1607 HERB TEA study). Presented at the 2023 San Antonio Breast Cancer Symposium; December 5-9; San Antonio, Texas. Abstract RF02-04